Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SIMPONI to Arrest β-cell Loss in Type 1 Diabetes

Next Previous
X
Search
Trial Profile

SIMPONI to Arrest β-cell Loss in Type 1 Diabetes

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Acronyms T1GER
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 28 Dec 2022 Results of two-year follow-up from the T1GER Study assessing benefits of the tumor necrosis factor-alpha blocker golimumab in children and young adults with type 1 diabetes published in the Diabetes Care
    • 27 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 19 Nov 2020 Results published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top